Yemaachi is doing well. The company continues to grow its unique genomic database by adding new clinical partners and expanding the amount of data available for research and discovery.

It is also working with an increasing number of data and pharmaceutical partners to generate valuable insights from the database. In addition, Yemaachi has recently launched a Series A fundraising campaign to support the next phase of growth.

The Imperial team's insights were very helpful in shaping the roadmap for Uvosyo. Yemaachi is currently working on the next version of the platform, and the team's recommendation to consider commercialisation of the platform has influenced several aspects of the new feature set and overall product strategy.

Yemaachi thanks the students for the interest, dedication, and quality of work they demonstrated in such a short period of time. The company greatly appreciates their contributions and thoughtful recommendations, and wishes them every success in their future studies, careers, and entrepreneurial endeavours.